Skip to main content
SpringerLink
Log in

Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer

  • Lung Cancer (H Borghaei, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Small cell lung cancer (SCLC) is an exceptionally lethal subtype of lung cancer. For patients with extensive-stage (ES) disease, which is the majority of patients, platinum-doublet chemotherapy has been the standard of care for decades. Dozens of phase III trials have failed to improve survival over standard platinum plus etoposide. Recent results, however, have met with long-overdue success. This manuscript reviews the new standards of care for ES-SCLC.

Recent Findings

Two recent phase III trials have shown an improvement in overall survival with concurrent immunotherapy and chemotherapy. In IMpower 133, the addition of the anti-PD-L1 antibody atezolizumab to carboplatin plus etoposide significantly improved both progression-free survival (PFS) and overall survival (OS). This was the first trial in over 30 years to improve survival. In CASPIAN, concurrent durvalumab, another anti-PD-L1 antibody, also led to an improvement in survival.

Summary

While there is clearly a need to further improve outcomes, the improvement in survival with the addition of atezolizumab or durvalumab to platinum-doublet chemotherapy is a major advance. We now have new standards of care and the potential of a more meaningful benefit for patients with advanced SCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.

    Article  Google Scholar 

  2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44. https://doi.org/10.1200/JCO.2005.04.4859.

    Article  PubMed  Google Scholar 

  3. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969;46(4):516–25.

    Article  CAS  Google Scholar 

  4. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–11. https://doi.org/10.1016/j.jtho.2015.10.008.

    Article  PubMed  Google Scholar 

  5. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549–61. https://doi.org/10.1038/nrclinonc.2017.71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shepherd FA. The role of chemotherapy in the treatment of small cell lung cancer. Chest Surg Clin N Am. 1997;7(1):113–33.

    CAS  PubMed  Google Scholar 

  7. Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 1979;44(2):406–13. https://doi.org/10.1002/1097-0142(197908)44:2<406::aid-cncr2820440206>3.0.co;2-1.

    Article  CAS  PubMed  Google Scholar 

  8. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet. 1996;348(9027):563–566. doi:https://doi.org/10.1016/s0140-6736(96)02005-3.

  9. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89(8):577–80. https://doi.org/10.1093/jnci/89.8.577.

    Article  CAS  PubMed  Google Scholar 

  10. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10(2):282–91. https://doi.org/10.1200/JCO.1992.10.2.282.

    Article  CAS  PubMed  Google Scholar 

  11. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17(6):1794–801. https://doi.org/10.1200/JCO.1999.17.6.1794.

    Article  CAS  PubMed  Google Scholar 

  12. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23–36. https://doi.org/10.1016/s0169-5002(00)00127-6.

    Article  CAS  PubMed  Google Scholar 

  13. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8–15. https://doi.org/10.1054/bjoc.2000.1164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8. https://doi.org/10.1200/JCO.2011.40.4905.

    Article  CAS  PubMed  Google Scholar 

  15. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91. https://doi.org/10.1056/NEJMoa003034.

    Article  CAS  PubMed  Google Scholar 

  16. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038–43. https://doi.org/10.1200/JCO.2005.04.8595.

    Article  CAS  PubMed  Google Scholar 

  17. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–5. https://doi.org/10.1200/JCO.2008.20.1061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–6. https://doi.org/10.1093/annonc/mdq036.

    Article  CAS  PubMed  Google Scholar 

  19. Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011;22(8):1798–1804. doi:https://doi.org/10.1093/annonc/mdq652.

  20. Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752–9. https://doi.org/10.1200/JCO.2005.09.071.

    Article  CAS  PubMed  Google Scholar 

  21. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001;12(4):463–70. https://doi.org/10.1023/a:1011131303391.

    Article  CAS  PubMed  Google Scholar 

  22. Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol. 1997;15(5):2082–9. https://doi.org/10.1200/JCO.1997.15.5.2082.

    Article  CAS  PubMed  Google Scholar 

  23. Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995;13(10):2594–9. https://doi.org/10.1200/JCO.1995.13.10.2594.

    Article  CAS  PubMed  Google Scholar 

  24. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(8):2114–22. https://doi.org/10.1200/JCO.2001.19.8.2114.

    Article  CAS  PubMed  Google Scholar 

  25. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. https://doi.org/10.1126/science.aaa1348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1038/nature12477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Armstrong SA, Liu SV. Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. Adv Ther. 2019;36(8):1826–32. https://doi.org/10.1007/s12325-019-01008-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. • Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33(abstr):7503 This important paper outlined CheckMate 032, one of the larger initial studies of checkpoint inhibitors (nivolumab and ipilimumab) in relapsed SCLC.

    Article  Google Scholar 

  29. • Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JH, Kao S, Miller Jr. WH et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): results from the KEYNOTE-028 and KEYNOTE-158 studies. Proceedings of the American Association for Cancer Research Annual Meeting 2019. 2019;79 (13 Suppl):Abstract nr CT073. This abstract outlined the activity of pembrolizumab as a third-line treatment option in advanced, relapsed SCLC, leading to the accelerated approval of pembrolizumab as third-line monotherapy.

  30. Destefano CB, Liu SV. Combinatorial Immunotherapy and Chemotherapy. In: Patel SP, Kurzrock R, editors. Early phase cancer immunotherapy. 1 ed. Current cancer research. Cham, Springer International Publishing; 2018. p. 199–218.

  31. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83. https://doi.org/10.1093/annonc/mds213.

    Article  CAS  PubMed  Google Scholar 

  32. • Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–8. https://doi.org/10.1200/JCO.2016.67.6601 This is an important negative result: the addition of ipilimumab to first-line chemotherapy did not improve survival, in contrast to anti-PD-L1 antibodies.

    Article  CAS  PubMed  Google Scholar 

  33. •• Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1809064 This reference provides the landmark results from IMpower 133, the randomized phase III trial of carboplatin and etoposide with atezolizumab or placebo. The addition of atezolizumab improved overall survival. This trial was the first in over 30 years to improve overall survival for patients with extensive-stage SCLC.

  34. • Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Lancet. 2019. https://doi.org/10.1016/S0140-6736(19)32222-6 This reference provides results from the open-label, randomized phase III CASPIAN trial, showing a survival benefit with adding durvalumab to platinum-doublet chemotherapy.

  35. Rudin CM, Shen L, Pietanza MC. KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC). Ann Oncol. 2017;28(suppl_5):v539–v42.

    Article  Google Scholar 

  36. Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13(9):1393–9. https://doi.org/10.1016/j.jtho.2018.05.002.

    Article  PubMed  PubMed Central  Google Scholar 

  37. • Owonikoko T, Kim HR, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase III CheckMate 451 study. Ann Oncol. 2019;30(Supplement_2, April 2019):LBA1_PR This abstract reported the results from CheckMate 451, a maintenance immunotherapy study. The use of maintenance nivolumab plus ipilimumab after chemotherapy did not improve survival over placebo, a critical negative result.

    Google Scholar 

  38. Reck M, Liu SV, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. IMpower 133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2019;30(suppl_5):v710–v7.

    Article  Google Scholar 

  39. Paz-Ares L, Goldman JW, Garassino MC, Dvorkin M, Trukhin D, Statsenko G, et al. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN. Ann Oncol. 2019;30(suppl_5):v851–934.

    Google Scholar 

  40. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987;5(11):1731–8. https://doi.org/10.1200/JCO.1987.5.11.1731.

    Article  CAS  PubMed  Google Scholar 

  41. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12(10):2022–34. https://doi.org/10.1200/JCO.1994.12.10.2022.

    Article  CAS  PubMed  Google Scholar 

  42. Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer. 1996;32A(9):1498–503. https://doi.org/10.1016/0959-8049(96)00145-1.

    Article  CAS  PubMed  Google Scholar 

  43. Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 1998;16(6):2126–32. https://doi.org/10.1200/JCO.1998.16.6.2126.

    Article  CAS  PubMed  Google Scholar 

  44. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999;17(8):2300–8. https://doi.org/10.1200/JCO.1999.17.8.2300.

    Article  CAS  PubMed  Google Scholar 

  45. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665–72. https://doi.org/10.1200/JCO.2002.12.111.

    Article  CAS  PubMed  Google Scholar 

  46. Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, et al. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a phase III trial of the Hellenic Oncology Research Group. Clin Lung Cancer. 2005;7(3):183–9. https://doi.org/10.3816/CLC.2005.n.034.

    Article  CAS  PubMed  Google Scholar 

  47. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer. 2008;99(3):442–7. https://doi.org/10.1038/sj.bjc.6604480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787–92. https://doi.org/10.1200/JCO.2009.23.1548.

    Article  CAS  PubMed  Google Scholar 

  49. Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7(9):1432–9. https://doi.org/10.1097/JTO.0b013e318260de75.

    Article  CAS  PubMed  Google Scholar 

  50. Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014;32(12):1262–8. https://doi.org/10.1200/JCO.2013.53.5153.

    Article  CAS  PubMed  Google Scholar 

  51. Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, et al. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. Clin Lung Cancer. 2014;15(2):96–102. https://doi.org/10.1016/j.cllc.2013.11.006.

    Article  CAS  PubMed  Google Scholar 

  52. Sun Y, Cheng Y, Hao X, Wang J, Hu C, Han B, et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016;16:265. https://doi.org/10.1186/s12885-016-2301-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, et al. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. BMC Cancer. 2016;16:690. https://doi.org/10.1186/s12885-016-2741-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Jalal SI, Lavin P, Lo G, Lebel F, Einhorn L. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: a multicenter, adaptive, randomized phase III study (MATISSE). J Clin Oncol. 2017;35(23):2619–23. https://doi.org/10.1200/JCO.2016.71.7454.

    Article  CAS  PubMed  Google Scholar 

  55. Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung Cancer: the GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol. 2017;35(12):1281–7. https://doi.org/10.1200/JCO.2016.69.4844.

    Article  CAS  PubMed  Google Scholar 

  56. Cheng Y, Fan Y, Liu X, Liu Y, Liu J, Wang D, et al. Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer. Oncol Lett. 2019;17(5):4701–9. https://doi.org/10.3892/ol.2019.10125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA

    Samantha A. Armstrong & Stephen V. Liu

Authors
  1. Samantha A. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen V. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen V. Liu.

Ethics declarations

Conflict of Interest

Samantha A. Armstrong declares that she has no conflict of interest.

Stephen V. Liu has received research funding from Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Clovis Oncology, Corvus Pharmaceuticals, Debiopharm, Esanex, Genentech/Roche, Eli Lilly, Lycera, Merck/MSD, Merus, Molecular Partners, Pfizer, Rain Therapeutics, RAPT Therapeutics, Spectrum, Takeda/ARIAD, Turning Point Therapeutics, and Ignyta; has received compensation from Apollomics, AstraZeneca, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Eli Lilly, Loxo Oncology, Merck/MSD, Pfizer, PharmaMar, S.A., Regeneron Pharmaceuticals, Taiho Oncology, Takeda/ARIAD, Ignyta, and Tempus; and has received non-financial support from AstraZeneca, Genentech/Roche, and Merck/MSD.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Armstrong, S.A., Liu, S.V. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer. Curr Oncol Rep 22, 20 (2020). https://doi.org/10.1007/s11912-020-0887-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-0887-y

Keywords

Search

Navigation